Attenuation of nephritis in lupus-prone mice by thalidomide

Sang Won Lee, YongBeom Park, Jaeseok Yang, Kyu Hyung Park, Soo Kon Lee, Kyu Hun Choi, Beom Seok Kim

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objectives:Thalidomide has various effects, such as immune modulation, anti-angiogenicity, antiinflammation and anti-proliferation. Moreover, thalidomide modulates the activity of NF-kB, which can up-regulate the expression of downstream genes involved in the pathophysiology of LN. Here we investigated the efficacy of thalidomide monotherapy or thalidomide plus prednisolone (PL) on nephritis in NZB/ WF1 mice at different doses and compared both with a combination therapy of MMF plus PL. Methods: Forty-three female NZB/WF1 mice were divided into eight groups (untreated; 1.7, 5 or 10mg/kg of thalidomide alone; 1.7, 5 or 10mg/kg of thalidomide plus 1.5mg/kg of PL and 33.3mg/kg of MMF plus PL). Proteinuria and histological damage were evaluated. Immune complex deposition and nuclear translocation of NF-kB in kidney tissues were assessed by immunofluorescence staining. Serum concentrations of anti-dsDNA and IgG subclasses were also measured. Results:In comparison with untreated mice, mice treated with 10mg/kg of thalidomide monotherapy showed a significant decrease in proteinuria and significantly lower glomerular and tubular damage scores, comparable to 5 or 10mg/kg of thalidomide plus PL or MMF plus PL. Also, treatment with 10mg/kg of thalidomide significantly decreased immune complex accumulation, reduced the serum concentration of anti-dsDNA, IgG2a and IgG2b and inhibited nuclear translocation of NF-kB in kidney tissues, comparable to standard therapy for LN. Conclusion: These data suggest that thalidomide might play an anti-inflammatory role in the pathophysiology of LN, and it could serve as a complementary therapy to standard induction regimens for refractory LN.

Original languageEnglish
Article numberkes227
Pages (from-to)2131-2140
Number of pages10
JournalRheumatology (United Kingdom)
Volume51
Issue number12
DOIs
Publication statusPublished - 2012 Dec 1

Fingerprint

Lupus Nephritis
Thalidomide
Prednisolone
NF-kappa B
Inbred NZB Mouse
Antigen-Antibody Complex
Proteinuria
Kidney
Nephritis
Complementary Therapies
Serum
Fluorescent Antibody Technique
Anti-Inflammatory Agents
Up-Regulation
Therapeutics
Staining and Labeling
Gene Expression

All Science Journal Classification (ASJC) codes

  • Rheumatology
  • Pharmacology (medical)

Cite this

Lee, S. W., Park, Y., Yang, J., Park, K. H., Lee, S. K., Choi, K. H., & Kim, B. S. (2012). Attenuation of nephritis in lupus-prone mice by thalidomide. Rheumatology (United Kingdom), 51(12), 2131-2140. [kes227]. https://doi.org/10.1093/rheumatology/kes227
Lee, Sang Won ; Park, YongBeom ; Yang, Jaeseok ; Park, Kyu Hyung ; Lee, Soo Kon ; Choi, Kyu Hun ; Kim, Beom Seok. / Attenuation of nephritis in lupus-prone mice by thalidomide. In: Rheumatology (United Kingdom). 2012 ; Vol. 51, No. 12. pp. 2131-2140.
@article{6d11bd53f7874503a0ec222b9ce7ef1f,
title = "Attenuation of nephritis in lupus-prone mice by thalidomide",
abstract = "Objectives:Thalidomide has various effects, such as immune modulation, anti-angiogenicity, antiinflammation and anti-proliferation. Moreover, thalidomide modulates the activity of NF-kB, which can up-regulate the expression of downstream genes involved in the pathophysiology of LN. Here we investigated the efficacy of thalidomide monotherapy or thalidomide plus prednisolone (PL) on nephritis in NZB/ WF1 mice at different doses and compared both with a combination therapy of MMF plus PL. Methods: Forty-three female NZB/WF1 mice were divided into eight groups (untreated; 1.7, 5 or 10mg/kg of thalidomide alone; 1.7, 5 or 10mg/kg of thalidomide plus 1.5mg/kg of PL and 33.3mg/kg of MMF plus PL). Proteinuria and histological damage were evaluated. Immune complex deposition and nuclear translocation of NF-kB in kidney tissues were assessed by immunofluorescence staining. Serum concentrations of anti-dsDNA and IgG subclasses were also measured. Results:In comparison with untreated mice, mice treated with 10mg/kg of thalidomide monotherapy showed a significant decrease in proteinuria and significantly lower glomerular and tubular damage scores, comparable to 5 or 10mg/kg of thalidomide plus PL or MMF plus PL. Also, treatment with 10mg/kg of thalidomide significantly decreased immune complex accumulation, reduced the serum concentration of anti-dsDNA, IgG2a and IgG2b and inhibited nuclear translocation of NF-kB in kidney tissues, comparable to standard therapy for LN. Conclusion: These data suggest that thalidomide might play an anti-inflammatory role in the pathophysiology of LN, and it could serve as a complementary therapy to standard induction regimens for refractory LN.",
author = "Lee, {Sang Won} and YongBeom Park and Jaeseok Yang and Park, {Kyu Hyung} and Lee, {Soo Kon} and Choi, {Kyu Hun} and Kim, {Beom Seok}",
year = "2012",
month = "12",
day = "1",
doi = "10.1093/rheumatology/kes227",
language = "English",
volume = "51",
pages = "2131--2140",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "12",

}

Lee, SW, Park, Y, Yang, J, Park, KH, Lee, SK, Choi, KH & Kim, BS 2012, 'Attenuation of nephritis in lupus-prone mice by thalidomide', Rheumatology (United Kingdom), vol. 51, no. 12, kes227, pp. 2131-2140. https://doi.org/10.1093/rheumatology/kes227

Attenuation of nephritis in lupus-prone mice by thalidomide. / Lee, Sang Won; Park, YongBeom; Yang, Jaeseok; Park, Kyu Hyung; Lee, Soo Kon; Choi, Kyu Hun; Kim, Beom Seok.

In: Rheumatology (United Kingdom), Vol. 51, No. 12, kes227, 01.12.2012, p. 2131-2140.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Attenuation of nephritis in lupus-prone mice by thalidomide

AU - Lee, Sang Won

AU - Park, YongBeom

AU - Yang, Jaeseok

AU - Park, Kyu Hyung

AU - Lee, Soo Kon

AU - Choi, Kyu Hun

AU - Kim, Beom Seok

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Objectives:Thalidomide has various effects, such as immune modulation, anti-angiogenicity, antiinflammation and anti-proliferation. Moreover, thalidomide modulates the activity of NF-kB, which can up-regulate the expression of downstream genes involved in the pathophysiology of LN. Here we investigated the efficacy of thalidomide monotherapy or thalidomide plus prednisolone (PL) on nephritis in NZB/ WF1 mice at different doses and compared both with a combination therapy of MMF plus PL. Methods: Forty-three female NZB/WF1 mice were divided into eight groups (untreated; 1.7, 5 or 10mg/kg of thalidomide alone; 1.7, 5 or 10mg/kg of thalidomide plus 1.5mg/kg of PL and 33.3mg/kg of MMF plus PL). Proteinuria and histological damage were evaluated. Immune complex deposition and nuclear translocation of NF-kB in kidney tissues were assessed by immunofluorescence staining. Serum concentrations of anti-dsDNA and IgG subclasses were also measured. Results:In comparison with untreated mice, mice treated with 10mg/kg of thalidomide monotherapy showed a significant decrease in proteinuria and significantly lower glomerular and tubular damage scores, comparable to 5 or 10mg/kg of thalidomide plus PL or MMF plus PL. Also, treatment with 10mg/kg of thalidomide significantly decreased immune complex accumulation, reduced the serum concentration of anti-dsDNA, IgG2a and IgG2b and inhibited nuclear translocation of NF-kB in kidney tissues, comparable to standard therapy for LN. Conclusion: These data suggest that thalidomide might play an anti-inflammatory role in the pathophysiology of LN, and it could serve as a complementary therapy to standard induction regimens for refractory LN.

AB - Objectives:Thalidomide has various effects, such as immune modulation, anti-angiogenicity, antiinflammation and anti-proliferation. Moreover, thalidomide modulates the activity of NF-kB, which can up-regulate the expression of downstream genes involved in the pathophysiology of LN. Here we investigated the efficacy of thalidomide monotherapy or thalidomide plus prednisolone (PL) on nephritis in NZB/ WF1 mice at different doses and compared both with a combination therapy of MMF plus PL. Methods: Forty-three female NZB/WF1 mice were divided into eight groups (untreated; 1.7, 5 or 10mg/kg of thalidomide alone; 1.7, 5 or 10mg/kg of thalidomide plus 1.5mg/kg of PL and 33.3mg/kg of MMF plus PL). Proteinuria and histological damage were evaluated. Immune complex deposition and nuclear translocation of NF-kB in kidney tissues were assessed by immunofluorescence staining. Serum concentrations of anti-dsDNA and IgG subclasses were also measured. Results:In comparison with untreated mice, mice treated with 10mg/kg of thalidomide monotherapy showed a significant decrease in proteinuria and significantly lower glomerular and tubular damage scores, comparable to 5 or 10mg/kg of thalidomide plus PL or MMF plus PL. Also, treatment with 10mg/kg of thalidomide significantly decreased immune complex accumulation, reduced the serum concentration of anti-dsDNA, IgG2a and IgG2b and inhibited nuclear translocation of NF-kB in kidney tissues, comparable to standard therapy for LN. Conclusion: These data suggest that thalidomide might play an anti-inflammatory role in the pathophysiology of LN, and it could serve as a complementary therapy to standard induction regimens for refractory LN.

UR - http://www.scopus.com/inward/record.url?scp=84870325735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870325735&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/kes227

DO - 10.1093/rheumatology/kes227

M3 - Article

C2 - 22923758

AN - SCOPUS:84870325735

VL - 51

SP - 2131

EP - 2140

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 12

M1 - kes227

ER -